Holen Sie sich die Stockscreener-App
2.42
1.22%
-0.03
Handel nachbörslich:
2.44
0.02
+0.83%
Schlusskurs vom Vortag:
$2.45
Offen:
$2.45
24-Stunden-Volumen:
23,764
Relative Volume:
0.10
Marktkapitalisierung:
$6.56M
Einnahmen:
$202.00K
Nettoeinkommen (Verlust:
$-28.96M
KGV:
-4.0333
EPS:
-0.6
Netto-Cashflow:
$-21.85M
1W Leistung:
-6.20%
1M Leistung:
-14.49%
6M Leistung:
+1,693%
1J Leistung:
+604.92%
1-Tages-Spanne:
$2.35
$2.5123
1-Wochen-Bereich:
$2.35
$2.6296
52-Wochen-Spanne:
$0.0633
$20.35
AIM ImmunoTech Inc Stock (AIM) Company Profile
Firmenname
AIM ImmunoTech Inc
Sektor
Branche
Telefon
352 448 7797
Adresse
2117 SW Highway 484, Ocala, FL
Vergleichen Sie AIM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
2.42 | 6.64M | 202.00K | -28.96M | -21.85M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.00 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.90 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.00 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
706.41 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.04 | 36.38B | 3.81B | -644.79M | -669.77M | -6.24 |
AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten
AIM ImmunoTech receives NYSE American notice of delisting and appeal - MSN
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders - Quantisnow
AIM ImmunoTech releases CEO Corner segment - MSN
AIM ImmunoTech Releases CEO Corner Segment, Discusses Recent Progress with Ampligen - AInvest
AIM ImmunoTech Announces CEO Corner Segment Release - AInvest
AIM ImmunoTech Announces Release of the Next CEO Corner Segment - GlobeNewswire
Biotech AIM ImmunoTech's CEO Details Progress of Promising Pancreatic Cancer Drug Ampligen in Latest Update - Stock Titan
AIM ImmunoTech's Oncology Gambit: Can Pancreatic Cancer Breakthroughs and Financial Stability Fuel a Biotech Comeback? - AInvest
AIM ImmunoTech reports Q2 EPS ($3.68) vs ($3.00) last year - MSN
AIM ImmunoTech Reports Q2 Losses Amid Ongoing Trials, Revenue Down to $25k. - AInvest
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Promising Pancreatic Cancer Treatment: AIM ImmunoTech's Ampligen Shows Strong Safety Data in Phase 2 - Stock Titan
Webull Corporation shares rise 1.49% premarket after AIM ImmunoTech and Moleculin Biotech to present at Webull Financial Corporate Connect Webinar Series. - AInvest
AIM ImmunoTech Reports Increased Losses Amid Ongoing Trials - TipRanks
AIM ImmunoTech to present at Webull Financial Corporate Connect webinar. - AInvest
AIM ImmunoTech CEO to Share Company Updates at Webull's Biotech Investment Series - Stock Titan
AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewswire
AIM ImmunoTech Presents at Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. - AInvest
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering - 富途牛牛
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in - GlobeNewswire
AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Pr - GuruFocus
Breakthrough: New Cancer Drug Ampligen Delivers Promising Results in Pancreatic, Ovarian, and Breast Cancer Trials - Stock Titan
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) - The Manila Times
AIM ImmunoTech (AIM) Advances Clinical Trials and Strengthens Financial Position - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval | AIM Stock News - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates - GlobeNewswire
Breakthrough in Pancreatic Cancer Treatment: AIM's Ampligen-Imfinzi Combo Shows Positive Survival Data - Stock Titan
AIM ImmunoTech Surges Amid Key Developments, Raises $8 Million in Public Offering - AInvest
AIM ImmunoTech Closes $8 Million Public Offering - The Globe and Mail
Latest News - Asia Food Journal
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering - GlobeNewswire
AIM ImmunoTech's $8.0M Capital Raise: A Strategic Move to Fuel Ampligen's Clinical Progress and Investor Value? - AInvest
AIM ImmunoTech closes public offering, raises $8 mln. - AInvest
AIM ImmunoTech Secures $8M Funding: New Shares at $4.00 Plus 5-Year Warrants - Stock Titan
AIM ImmunoTech reports Ampligen combo trial data for pancreatic cancer - MSN
Biotech Alert: Searches spiking for these stocks today - TipRanks
AIM ImmunoTech's Stock Falls 50% Following $8M Securities Offering - AInvest
Evaluating AIM ImmunoTech's Capital Raise: A Strategic Crossroads for Investors - AInvest
AIM Shares Fall After Pricing of $8 Million Public Offering - MarketScreener
Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views - Benzinga
AIM ImmunoTech stock plunges after pricing $8 million public offering By Investing.com - Investing.com Australia
AIM ImmunoTech stock plunges after pricing $8 million public offering - Investing.com
US Stocks Mixed; Procter & Gamble Posts Upbeat Earnings - Benzinga
AIM ImmunoTech Stock Dives 50% After Priced Public Offering - AInvest
Why Is AIM ImmunoTech Stock (AIM) Down 50% Today? - TipRanks
AIM ImmunoTech prices $8 million public offering at $4.00 per share - Investing.com
AIM ImmunoTech Plunges 51.11% Amid Market Volatility - AInvest
AIM ImmunoTech prices 2M shares at $4.00 in public offering - TipRanks
Finanzdaten der AIM ImmunoTech Inc-Aktie (AIM)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):